Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion type Assertion NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_head.
- NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion description "[An elevated RANK/OPG ratio was associated with shorter median time to metastasis (HR 0.50 (95% CI 0.29-0.87); P=0.014), shorter time to BM (HR 0.54 (95% CI 0.31-0.97); P=0.037), shorter median overall survival (mOS) since initial diagnosis (HR 2.27 (95% CI 1.44-3.60); P=0.0001), shorter median progression-free survival (HR 0.44 (95% CI 0.28-0.71); P=0.001) and mOS (HR 0.31 (95% CI 0.19-0.52); P<0.0001) on first-line anti-VEGFR-TKIs in the metastatic setting.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_provenance.
- NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion evidence source_evidence_literature NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_provenance.
- NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion SIO_000772 26528707 NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_provenance.
- NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion wasDerivedFrom befree-2016 NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_provenance.
- NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_assertion wasGeneratedBy ECO_0000203 NP1295376.RAPkxP9uoeaeubfhdAVKfiZE5za-eUOGg6qex_Of_W4b4130_provenance.